alpha-aminopyridine has been researched along with Granulocytic Leukemia, Chronic in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 6 (54.55) | 2.80 |
| Authors | Studies |
|---|---|
| Ji, C; Li, P; Liu, N; Liu, Q; Ma, D; Sun, Y; Wang, Y; Ye, J; Yu, S; Zhang, J; Zhu, X | 1 |
| Jiang, L; Yang, M | 1 |
| Bai, YL; Chen, CY; Chen, SN; Du, X; Guo, JX; Han, YQ; Hu, JD; Huang, J; Jiang, Q; Li, F; Li, GH; Li, WM; Liang, R; Lin, H; Lin, LE; Liu, BC; Liu, CS; Liu, XL; Liu, ZF; Liu, ZG; Liu, ZL; Meng, L; Pan, L; Pang, LP; Qiu, HY; Sun, H; Sun, XL; Suo, XH; Tu, CQ; Wang, DY; Wang, XD; Xu, N; Yang, LJ; Yang, W; Yang, YF; Zeng, QS; Zhang, WH; Zhang, XS; Zhang, YL; Zhang, YQ; Zhao, ZY; Zheng, CF; Zheng, YJ; Zhou, L; Zhou, ZP; Zhu, HL | 1 |
| Chen, C; Fu, Y; Huang, T; Wang, S; Wang, X; Xu, M; Yin, X; Zhou, M | 1 |
| Bashash, D; Hamidpour, M; Safaroghli-Azar, A; Shiri Heris, R; Yousefi, AM | 1 |
| Cui, J; Gu, J; Hu, Y; Jiang, H; Jiang, M; Jin, J; Li, J; Li, Y; Liu, B; Liu, L; Liu, X; Luo, J; Meng, L; Ouyang, G; Qiao, J; Sun, A; Wang, J; Xie, X; Yang, T; Zhang, L; Zhang, M; Zhang, W; Zhang, X; Zhang, Y; Zhao, C; Zhu, H | 1 |
| Müller, MC | 1 |
| Cheng, C; Gao, WQ; He, Y; Ji, Z; Li, L; Liu, K; Maguer-Satta, V; Sheng, Y; Voeltzel, T; Wang, J; Wang, X; Xu, W; Zhao, H; Zhu, HH | 1 |
| Chen, X; Deng, P; Gong, A; Zhong, D | 1 |
| Fu, L; Lou, L; Luo, H; Quan, H; Xie, C; Xu, Y | 1 |
| Chen, X; Liu, K; Yang, Y; Zhong, D | 1 |
11 other study(ies) available for alpha-aminopyridine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.
Topics: alpha-Crystallin B Chain; Aminopyridines; Apoptosis; Benzamides; Down-Regulation; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs | 2022 |
Clinical Efficacy and Safety of Flumatinib in Newly Diagnosed Chronic Myelogenous Leukemia.
Topics: Aminopyridines; Antineoplastic Agents; Benzamides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2023 |
[To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Topics: Adolescent; Adult; Aminopyridines; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Protein Kinase Inhibitors; Pyrimidines; Retrospective Studies; Treatment Outcome | 2023 |
miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Topics: 3' Untranslated Regions; Aminopyridines; Base Sequence; Benzamides; Blast Crisis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Decitabine; Down-Regulation; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MicroRNAs; Oncogenes; Protein Biosynthesis | 2019 |
Anti-leukemic effect of PI3K inhibition on chronic myeloid leukemia (CML) cells: shedding new light on the mitigating effect of c-Myc and autophagy on BKM120 cytotoxicity.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Autophagy; Cell Survival; G2 Phase Cell Cycle Checkpoints; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Morpholines; Phosphoinositide-3 Kinase Inhibitors | 2020 |
Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Piperazines; Pyrimidines; Treatment Outcome | 2021 |
New Drug for Chronic Myeloid Leukemia Might Stimulate the Market.
Topics: Aminopyridines; Benzamides; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2021 |
Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Hydrazones; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors | 2019 |
Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Agents; Benzamides; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Molecular Structure; Protein Kinase Inhibitors; Young Adult | 2010 |
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Nude; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Simultaneous determination of flumatinib and its two major metabolites in plasma of chronic myelogenous leukemia patients by liquid chromatography-tandem mass spectrometry.
Topics: Aminopyridines; Antineoplastic Agents; Benzamides; Chromatography, Liquid; Drug Stability; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2012 |